123 related articles for article (PubMed ID: 37245332)
1. Comparison of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults with Philadelphia-negative acute lymphoblastic leukemia: A multicenter retrospective analysis.
Salama H; Eldadah S; Omer MH; Alhejazi A; Bin Dayil L; Almozaini A; Khalil RR; Mugairi AA; Snnallah M; Damlaj M; Alaskar A; Alsaeed A; Bakkar MM; Alahmari B; Alzahrani M; Elhemaidi I; Alahmadi M; Alamoudi S; Rajkhan W; Khalil M; Kanfar SS; Saleh ASA; Raizah AA; Ibrahim A; Absi A
Leuk Res; 2023 Jul; 130():107316. PubMed ID: 37245332
[TBL] [Abstract][Full Text] [Related]
2. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.
Rytting ME; Jabbour EJ; Jorgensen JL; Ravandi F; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Borthakur G; Garris R; Wang S; Pierce S; Schroeder K; Kornblau SM; Thomas DA; Cortes JE; O'Brien SM; Kantarjian HM
Am J Hematol; 2016 Aug; 91(8):819-23. PubMed ID: 27178680
[TBL] [Abstract][Full Text] [Related]
3. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
Rytting ME; Thomas DA; O'Brien SM; Ravandi-Kashani F; Jabbour EJ; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Cortes JE; Borthakur G; Garris R; Cardenas-Turanzas M; Schroeder K; Jorgensen JL; Kornblau SM; Kantarjian HM
Cancer; 2014 Dec; 120(23):3660-8. PubMed ID: 25042398
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Two Pediatric-Inspired Regimens to Hyper-CVAD in Hispanic Adolescents and Young Adults With Acute Lymphoblastic Leukemia.
Almanza-Huante E; Espinosa-Bautista K; Rangel-Patiño J; Demichelis-Gómez R
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):55-62.e2. PubMed ID: 32893130
[TBL] [Abstract][Full Text] [Related]
5. The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience.
Alabdulwahab AS; Elsayed HG; Sherisher MA; Zeeneldin A; Alghamdi K; Elbjeirami WM
Leuk Res; 2017 Sep; 60():58-62. PubMed ID: 28704720
[TBL] [Abstract][Full Text] [Related]
6. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194
[TBL] [Abstract][Full Text] [Related]
7. Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults.
Guzauskas GF; Villa KF; Vanhove GF; Fisher VL; Veenstra DL
J Adolesc Young Adult Oncol; 2017 Mar; 6(1):53-61. PubMed ID: 27779442
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of Hyper-CVAD/MA and CHALL-01 regimens in the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia patients under 60 years old].
Huang AJ; Wang LB; Du J; Tang GS; Cheng H; Gong SL; Gao L; Qiu HY; Ni X; Chen J; Chen L; Zhang WP; Wang JM; Yang JM; Hu XX
Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):625-632. PubMed ID: 31495127
[No Abstract] [Full Text] [Related]
9. Effectiveness of modified hyper-CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience.
Jalaeikhoo H; Rajaeinejad M; Keyhani M; Zokaasadi M; Dehghani Firoozabadi MM
Cancer Med; 2018 Mar; 7(3):594-599. PubMed ID: 29383863
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
[TBL] [Abstract][Full Text] [Related]
11. Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study.
Erkut N; Akidan O; Selim Batur D; Karabacak V; Sonmez M
Chemotherapy; 2018; 63(4):207-213. PubMed ID: 30304722
[TBL] [Abstract][Full Text] [Related]
12. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Faderl S; Kantarjian HM; Thomas DA; Cortes J; Giles F; Pierce S; Albitar M; Estrov Z
Leuk Lymphoma; 2000 Jan; 36(3-4):263-73. PubMed ID: 10674898
[TBL] [Abstract][Full Text] [Related]
13. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Daver N; Thomas D; Ravandi F; Cortes J; Garris R; Jabbour E; Garcia-Manero G; Borthakur G; Kadia T; Rytting M; Konopleva M; Kantarjian H; O'Brien S
Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of the Hyper-CVAD with an institutional regimen for the treatment of acute lymphoblastic leukemia in adults in a hospital of Mexico].
Ramos-Peñafiel CO; Cabrera-García Á; Rozen-Fuller E; González-León G; Balderas C; Kassack-Ipiña JJ; Castellanos-Sinco H; Martínez-Murillo C; Montaño-Figueroa E; Martínez-Tovar A; Olarte-Carrillo I; Santoyo-Sánchez A; Collazo-Jaloma J
Rev Peru Med Exp Salud Publica; 2014; 31(3):525-9. PubMed ID: 25418653
[TBL] [Abstract][Full Text] [Related]
15. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
Thomas DA; O'Brien S; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Ravandi F; Verstovsek S; Jorgensen JL; Bueso-Ramos C; Andreeff M; Pierce S; Garris R; Keating MJ; Cortes J; Kantarjian HM
J Clin Oncol; 2010 Aug; 28(24):3880-9. PubMed ID: 20660823
[TBL] [Abstract][Full Text] [Related]
16. Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD.
Damlaj M; Snnallah M; Bashir R; Eddine IS; Alahmari B; Salama H; Alaskar A; Alhejazi A; Alzahrani M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):690-696. PubMed ID: 32636149
[TBL] [Abstract][Full Text] [Related]
17. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.
Jabbour E; Richard-Carpentier G; Sasaki Y; Konopleva M; Patel K; Roberts K; Gu Z; Wang F; Huang X; Sasaki K; Short NJ; Jain N; Ravandi F; Daver NG; Kadia TM; Alvarado Y; DiNardo CD; Issa GC; Pemmaraju N; Garcia-Manero G; Verstovsek S; Wang S; Khoury JD; Jorgensen J; Champlin R; Khouri I; Kebriaei P; Schroeder H; Khouri M; Mullighan CG; Takahashi K; O'Brien SM; Kantarjian H
Lancet Haematol; 2020 Jul; 7(7):e523-e533. PubMed ID: 32589978
[TBL] [Abstract][Full Text] [Related]
18. Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers.
Alacacioglu I; Medeni SS; Ozsan GH; Payzin B; Sevindik OG; Acar C; Katgi A; Ozdemirkan F; Piskin O; Ozcan MA; Undar B; Demirkan F
Chemotherapy; 2014; 60(4):219-23. PubMed ID: 25871894
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and outcome of the hyper-CVAD regimen in patients with adult acute lymphoblastic leukemia.
Portugal RD; Loureiro MM; Garnica M; Pulcheri W; Nucci M
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):52-7. PubMed ID: 25037887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]